What is Mnemo Therapeutics?
Founded in 2019 and based in Paris, France, Mnemo Therapeutics is a biotechnology firm dedicated to advancing cell therapy. The company leverages its EnfiniT platform, a sophisticated drug discovery engine, to pursue a novel, integrated approach in the development of cell therapies. Mnemo's mission is to engineer powerful cell therapies that can lead to accessible cures for a range of diseases, positioning itself at the forefront of therapeutic innovation in the life sciences sector.
How much funding has Mnemo Therapeutics raised?
Mnemo Therapeutics has raised a total of $90M across 1 funding round:
Series A
$90M
Series A (2021): $90M with participation from Redmile Group, Casdin Capital, Alexandria Venture Investments, Emerson Collective, and Sofinnova Partners
Key Investors in Mnemo Therapeutics
Redmile Group
Redmile Group is a venture capital firm operating within the life sciences sector, known for its investments in innovative biotechnology companies.
Casdin Capital
Casdin Capital is a venture capital firm with a deep understanding of life science innovation, focusing on financing next-generation advancements in the field.
Alexandria Venture Investments
Alexandria Venture Investments is an investment entity that supports companies within the life sciences and technology sectors.
What's next for Mnemo Therapeutics?
The recent major strategic investment signals a pivotal growth phase for Mnemo Therapeutics. This capital is expected to accelerate the company's research and development initiatives, potentially expanding its pipeline of cell therapies and further validating its EnfiniT platform. Mnemo's focus on creating accessible cures suggests a strategic direction aimed at addressing unmet medical needs, with future developments likely to concentrate on clinical progression and market entry. The company's trajectory indicates a strong commitment to translating scientific breakthroughs into tangible therapeutic solutions.
See full Mnemo Therapeutics company page
